

### Appendix 3. Childhood cancer, Western Australia, 2008 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%	
	Age Group								Age Group								Age Group								
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14					
<b>I. LEUKAEMIAS, MYELOPROLIFERATIVE AND MYELOYDYSPLASTIC DISEASES</b>																									
All		1	2	7	<b>10</b>	<b>4.1</b>	1.5-6.7	100	3	2	3		<b>8</b>	<b>3.9</b>	1.2-6.6	100	4	4	10		<b>18</b>	<b>4.0</b>	2.1-5.9	100	
		1.7	2.8	9.2					5.4	3.0	4.3						3.5	2.9	6.8						
Lymphoid leukaemia		1	2	3	<b>6</b>	<b>2.6</b>	0.5-4.7	100	3	1			<b>4</b>	<b>2.2</b>	0.0-4.3	100	4	3	3		<b>10</b>	<b>2.4</b>	0.9-3.9	100	
		1.7	2.8	4.0					5.4	1.5							3.5	2.2	2.1						
Acute myeloid leukaemia				4	<b>4</b>	<b>1.5</b>	0.0-3.0	100		1	3		<b>4</b>	<b>1.7</b>	0.0-3.4	100			1	7		<b>8</b>	<b>1.6</b>	0.5-2.8	100
				5.3						1.5	4.3								0.7	4.8					
Chronic MPDs					<b>0</b>								<b>0</b>								<b>0</b>				
MDS & other MPDs					<b>0</b>								<b>0</b>								<b>0</b>				
Unspecified/other leukaemia					<b>0</b>								<b>0</b>								<b>0</b>				
<b>II. LYMPHOMAS</b>																									
All		1	1	3	<b>7</b>	<b>3.2</b>	0.8-5.5	100			2		<b>2</b>	<b>0.8</b>	0 - 2.0	100	1	1	3	4	<b>9</b>	<b>2.0</b>	0.7-3.4	100	
		6.6	1.7	4.2	2.6						2.8						3.4	0.9	2.2	2.7					
Hodgkin lymphoma					<b>0</b>								<b>0</b>								<b>0</b>				
Non-Hodgkin lymphoma exc Burkitt		1		1	<b>4</b>	<b>1.7</b>	0.0-3.4	100			1		<b>1</b>	<b>0.4</b>	0 - 1.2	100	1		1	3	<b>5</b>	<b>1.1</b>	0.1-2.1	100	
		6.6		1.4	2.6						1.4						3.4		0.7	2.1					
Burkitt lymphoma			1	2	<b>3</b>	<b>1.4</b>	0 - 3.1	100			1		<b>1</b>	<b>0.4</b>	0 - 1.2	100			1	2	<b>4</b>	<b>0.9</b>	0.0-1.9	100	
			1.7	2.8							1.4								0.9	1.4	0.7				
Misc. lymphoreticular neoplasms					<b>0</b>								<b>0</b>								<b>0</b>				
Unspecified lymphoma					<b>0</b>								<b>0</b>								<b>0</b>				
<b>III. CNS AND INTRACRANIAL/SPINAL</b>																									
All		2	1	2	<b>5</b>	<b>2.3</b>	0.3-4.3	60		1	1		<b>2</b>	<b>0.9</b>	0 - 2.1	0	2	2	3		<b>7</b>	<b>1.6</b>	0.4-2.8	43	
		3.4	1.4	2.6						1.5	1.4						1.8	1.4	2.1						
Ependymoma/choroid plexus					<b>0</b>								<b>0</b>								<b>0</b>				
Astrocytoma		1	1		<b>2</b>	<b>1.0</b>	0 - 2.3	0					<b>0</b>				1	1			<b>2</b>	<b>0.5</b>	0 - 1.2	0	
		1.7	1.4														0.9	0.7							
Embryonal tumours		1		1	<b>2</b>	<b>0.9</b>	0 - 2.2	100					<b>0</b>				1		1		<b>2</b>	<b>0.5</b>	0 - 1.1	100	
		1.7		1.3													0.9		0.7						
Other gliomas					<b>0</b>					1	1		<b>2</b>	<b>0.9</b>	0 - 2.1	0			1	1	<b>2</b>	<b>0.4</b>	0 - 1.0	0	
										1.5	1.4								0.7	0.7					
Other intracranial/spinal				1	<b>1</b>	<b>0.4</b>	0 - 1.1	100					<b>0</b>							1	<b>1</b>	<b>0.2</b>	0 - 0.6	100	
				1.3																0.7					
Unspecified					<b>0</b>								<b>0</b>								<b>0</b>				

### Appendix 3. Childhood cancer, Western Australia, 2008 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%
	Age Group								Age Group								Age Group							
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
<b>IV. NEUROBLASTOMA &amp; PERIPHERAL NERVOUS SYSTEM TUMOURS</b>																								
All	2	1	1		<b>4</b>	<b>2.0</b>	0.0-4.0	100	3	1			<b>4</b>	<b>2.2</b>	0.0-4.3	75	5	2	1		<b>8</b>	<b>2.1</b>	0.6-3.5	88
	13.2	1.7	1.4						20.9	1.8							16.9	1.8	0.7					
Neuroblastoma/ganglioneurol.	2	1	1		<b>4</b>	<b>2.0</b>	0.0-4.0	100	3	1			<b>4</b>	<b>2.2</b>	0.0-4.3	75	5	2	1		<b>8</b>	<b>2.1</b>	0.6-3.5	88
	13.2	1.7	1.4						20.9	1.8							16.9	1.8	0.7					
Other					<b>0</b>								<b>0</b>								<b>0</b>			
<b>V. RETINOBLASTOMA</b>																								
All		1			<b>1</b>	<b>0.5</b>	0 - 1.6	100					<b>0</b>					1			<b>1</b>	<b>0.3</b>	0 - 0.8	100
		1.7																0.9						
<b>VI. RENAL TUMOURS</b>																								
All		1	1		<b>2</b>	<b>1.0</b>	0 - 2.3	100	1				<b>1</b>	<b>0.6</b>	0 - 1.7	100	2	1			<b>3</b>	<b>0.8</b>	0 - 1.7	100
		1.7	1.4						1.8								1.8	0.7						
Nephroblastoma/oth non-epithel.		1	1		<b>2</b>	<b>1.0</b>	0 - 2.3	100	1				<b>1</b>	<b>0.6</b>	0 - 1.7	100	2	1			<b>3</b>	<b>0.8</b>	0 - 1.7	100
		1.7	1.4						1.8								1.8	0.7						
Renal carcinoma					<b>0</b>								<b>0</b>								<b>0</b>			
Unspecified					<b>0</b>								<b>0</b>								<b>0</b>			
<b>VII. HEPATIC TUMOURS</b>																								
All					<b>0</b>								<b>0</b>								<b>0</b>			
Hepatoblastoma					<b>0</b>								<b>0</b>								<b>0</b>			
Hepatic carcinoma					<b>0</b>								<b>0</b>								<b>0</b>			
Unspecified					<b>0</b>								<b>0</b>								<b>0</b>			
<b>VIII. BONE</b>																								
All				2	<b>2</b>	<b>0.8</b>	0 - 1.8	100	1	3			<b>4</b>	<b>1.7</b>	0.0-3.4	100	1	5			<b>6</b>	<b>1.2</b>	0.2-2.2	100
				2.6					1.5	4.3							0.7	3.4						
Osteosarcoma				2	<b>2</b>	<b>0.8</b>	0 - 1.8	100	1	3			<b>4</b>	<b>1.7</b>	0.0-3.4	100	1	5			<b>6</b>	<b>1.2</b>	0.2-2.2	100
				2.6					1.5	4.3							0.7	3.4						
Chondrosarcoma					<b>0</b>								<b>0</b>								<b>0</b>			
Ewing & related sarcoma					<b>0</b>								<b>0</b>								<b>0</b>			
Other specified					<b>0</b>								<b>0</b>								<b>0</b>			
Unspecified					<b>0</b>								<b>0</b>								<b>0</b>			

### Appendix 3. Childhood cancer, Western Australia, 2008 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%
	Age Group								Age Group								Age Group							
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
<b>IX. SOFT TISSUE SARCOMA</b>																								
All			1	1	<b>2</b>	<b>0.8</b>	0 - 2.0	100				1	<b>1</b>	<b>0.4</b>	0 - 1.2	100			1	2	<b>3</b>	<b>0.6</b>	0 - 1.3	100
			1.4	1.3								1.4							0.7	1.4				
Rhabdomyosarcoma			1		<b>1</b>	<b>0.5</b>	0 - 1.3	100					<b>0</b>						1		<b>1</b>	<b>0.2</b>	0 - 0.7	100
			1.4																0.7					
Fibrosarcoma/Neurofibrosarc.				1	<b>1</b>	<b>0.4</b>	0 - 1.1	100					<b>0</b>							1	<b>1</b>	<b>0.2</b>	0 - 0.6	100
				1.3																0.7				
Kaposi sarcoma					<b>0</b>								<b>0</b>								<b>0</b>			
Other specified					<b>0</b>							1	<b>1</b>	<b>0.4</b>	0 - 1.2	100				1	<b>1</b>	<b>0.2</b>	0 - 0.6	100
												1.4								0.7				
Unspecified					<b>0</b>								<b>0</b>								<b>0</b>			
<b>X. GONADAL AND GERM CELL</b>																								
All		1			<b>1</b>	<b>0.5</b>	0 - 1.6	100				1	<b>1</b>	<b>0.4</b>	0 - 1.2	100			1	1	<b>2</b>	<b>0.5</b>	0 - 1.1	100
		1.7										1.4							0.9	0.7				
Intracranial/spinal					<b>0</b>								<b>0</b>								<b>0</b>			
Other/unspecified non-gonadal					<b>0</b>								<b>0</b>								<b>0</b>			
Gonadal germ cell		1			<b>1</b>	<b>0.5</b>	0 - 1.6	100				1	<b>1</b>	<b>0.4</b>	0 - 1.2	100			1	1	<b>2</b>	<b>0.5</b>	0 - 1.1	100
		1.7										1.4							0.9	0.7				
Gonadal carcinoma					<b>0</b>								<b>0</b>								<b>0</b>			
Other and unspecified					<b>0</b>								<b>0</b>								<b>0</b>			
<b>XI. OTHER EPITHELIAL / MELANOMA</b>																								
All				1	<b>1</b>	<b>0.4</b>	0 - 1.1	100	1				<b>1</b>	<b>0.5</b>	0 - 1.6	100	1			1	<b>2</b>	<b>0.5</b>	0 - 1.1	100
				1.3					7.0								3.4			0.7				
Adrenocortical carcinoma					<b>0</b>								<b>0</b>								<b>0</b>			
Thyroid carcinoma					<b>0</b>								<b>0</b>								<b>0</b>			
Nasopharyngeal carcinoma				1	<b>1</b>	<b>0.4</b>	0 - 1.1	100					<b>0</b>							1	<b>1</b>	<b>0.2</b>	0 - 0.6	100
				1.3																0.7				
Malignant melanoma					<b>0</b>								<b>0</b>								<b>0</b>			
Skin carcinomas					<b>0</b>								<b>0</b>								<b>0</b>			
Other/unspecified carcinoma					<b>0</b>				1				<b>1</b>	<b>0.5</b>	0 - 1.6	100	1				<b>1</b>	<b>0.3</b>	0 - 0.8	100
									7.0								3.4							

### Appendix 3. Childhood cancer, Western Australia, 2008 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%
	Age Group								Age Group								Age Group							
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
XII. OTHER																								
All	1				<b>1</b>	<b>0.5</b>	0 - 1.5	0					<b>0</b>				1				<b>1</b>	<b>0.3</b>	0 - 0.8	0
	6.6																3.4							
Other specified malignancy					<b>0</b>								<b>0</b>								<b>0</b>			
Other unspecified malignancy	1				<b>1</b>	<b>0.5</b>	0 - 1.5	0					<b>0</b>				1				<b>1</b>	<b>0.3</b>	0 - 0.8	0
	6.6																3.4							
<b>Total</b>	4	8	9	15	<b>36</b>	<b>16.1</b>	10.8-21.4	92	4	5	4	11	<b>24</b>	<b>11.4</b>	6.8-16.0	88	8	13	13	26	<b>60</b>	<b>13.8</b>	10.3-17.4	90
	26.3	13.7	12.6	19.8					27.8	9.1	5.9	15.7					27.0	11.5	9.4	17.8				